Phase 2 Brain Cancer Trial, Recruiting NCT07180927 Sponsor: Shenzhen Geno-Immune Medical Institute Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT07180927
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to understand the study and are willing to sign a written consent form
  • People aged 2 to 70 years old
  • People who have a brain tumor that has come back or has not responded to treatment, with tumors that can be measured on scans, and who have already received standard treatment such as surgery and radiation/chemotherapy; at the time of a white blood cell collection procedure, the person must either not be taking dexamethasone (a steroid) or be taking no more than 4 mg per day
  • People with a performance score showing they can carry out basic daily activities (Karnofsky score of 60 or above — confirm with trial site if unsure what this means)
  • People with a life expectancy of more than 3 months
  • People whose bone marrow, liver, and kidney are functioning at levels that meet the trial's required blood test results (the trial site can confirm whether specific results meet these levels)
  • People with a lymphocyte count (a type of white blood cell) above a certain level, as confirmed by a blood test
  • People with satisfactory heart function
  • People who are willing to follow the medical team's instructions throughout the study
  • Women of reproductive age (15–49 years old) who have a negative pregnancy test within 7 days of starting the study; people of reproductive potential must agree to use contraception during the study and for 3 months after it ends

Who may not be able to join:

  • People who have had a Gliadel wafer implant (a type of chemotherapy implant placed in the brain during surgery) within 4 weeks before the study starts, or who are currently receiving antibody-based treatments
  • People who are HIV positive
  • People who have tuberculosis that is not under control
  • People with a history of autoimmune disease, or any condition that requires long-term use of steroids or immune-suppressing medications
  • People with a history of allergic disease, or a known allergy to immune cells or the ingredients used in the study treatment
  • People who are already actively taking part in another clinical trial involving immune cell therapy, or people who the trial investigators believe may not be suitable or able to follow the study requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 0755-86573763

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shenzhen Geno-Immune Medical Institute
Registry
ClinicalTrials.gov
Start date
10 September 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Number of patients with adverse events.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov